FRESENIUS MEDICAL CARE AG & CO. KGAA

(FME)
  Report
Delayed Xetra  -  05/25 11:35:08 am EDT
56.70 EUR   +1.36%
02:46aFMC FRESENIUS MEDICAL CARE AG & CO KGAA : JP Morgan maintains a Sell rating
MD
05/24FMC FRESENIUS MEDICAL CARE AG & CO KGAA : Buy rating from Berenberg
MD
05/16FMC FRESENIUS MEDICAL CARE AG & CO KGAA : Buy rating from DZ Bank
MD
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

Fresenius Medical Care : FKC Partners with Biim Ultrasound AS

01/13/2022 | 11:01am EDT

Portable Ultrasound System Expands to Hundreds of Dialysis Centers to Assist Cannulation

WALTHAM, Mass. & NARVIK, Norway - Jan. 13, 2022 - Fresenius Kidney Care, the nation's leading provider of kidney care services, and Biim Ultrasound AS (Biim), announce an agreement to expand use of Biim's innovative ultrasound system for assisting needle cannulation prior to dialysis treatment.

Fresenius Kidney Care successfully piloted the use of Biim's ultrasound system at more than two dozen dialysis centers in 2020 in an effort to improve the patient experience and reduce access failures. The expanded rollout will involve hundreds of additional centers throughout the United States in early 2022. While often used in a hospital setting, ultrasound has not yet been widely or routinely used in outpatient dialysis centers to assist with cannulation.

"Our expanded use of Biim's technology reflects our commitment to offering the highest level of care for people living with kidney failure and in need of life sustaining dialysis treatment," said Mike Asselta, President of Fresenius Kidney Care. "The use of ultrasound is a tool we hope will enable our dedicated care teams to further improve the patient experience. In addition, this agreement further supports our commitment to creating value for patients and payors."

"We have received positive feedback from patients who notice a difference when cannulation is assisted by ultrasound," said Dr. Jeffrey Hymes, Chief Medical Officer of Fresenius Kidney Care and Executive Vice President, Global Head of Clinical Affairs for Fresenius Medical Care. "The use of ultrasound also has the potential to reduce the incidence of damage to the vascular access that is so critical to patient outcomes."

Biim is a fast, flexible, cordless ultrasound that has the ability to scan patients and review images in seconds, offering a practical way to enhance decision-making and help improve patient outcomes. The Biim system is easy to operate, with a simple app interface, so that scanning can begin within seconds.

"We are proud and of course very pleased that Fresenius Kidney Care has put its trust in Biim and our products by implementing our ultrasound system as part of their patients' treatments," said Rune Nystad, CEO of Biim. "For Biim, this agreement represents a major milestone, and we look forward to our continued partnership."

Fresenius Kidney Care is committed to further evaluating the impact of using ultrasound to assist with cannulation as this technology is made available to even more patients, including home patients during training. Following additional evaluation of the program, a broader distribution of Biim's ultrasound system is possible.

INDICATIONS FOR USE
The Biim® Diagnostic Ultrasound System is intended for diagnostic ultrasound imaging for the human body. Specific clinical applications include musculoskeletal, needle guidance, pediatric, peripheral vessel and small organs.

About Fresenius Kidney Care
Fresenius Kidney Care, a division of Fresenius Medical Care North America (FMCNA), provides dialysis treatment and support services to more than 200,000 people with kidney disease every year whether in their own homes or at more than 2,600 facilities nationwide. Fresenius Kidney Care's dedicated teams help address the physical and emotional aspects of kidney disease through personalized care, education, and lifestyle support services. For more information about Fresenius Kidney Care, visit freseniuskidneycare.com/

About Biim Ultrasound AS
Biim Ultrasound was founded in 2011 with the vision of making high quality, affordable point-of-care ultrasound imaging available to a broad range of trained medical professionals. The company is committed to improving patient care and reducing healthcare costs by enabling faster and easier diagnostic ultrasound imaging. The company is headquartered in Norway with subsidiaries in Finland and the USA. Visit https://biimultrasound.com/

Disclaimer

FMC - Fresenius Medical Care AG & Co. KGaA published this content on 13 January 2022 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 13 January 2022 16:00:03 UTC.


© Publicnow 2022
All news about FRESENIUS MEDICAL CARE AG & CO. KGAA
02:46aFMC FRESENIUS MEDICAL CARE AG & CO K : JP Morgan maintains a Sell rating
MD
05/24FMC FRESENIUS MEDICAL CARE AG & CO K : Buy rating from Berenberg
MD
05/16FMC FRESENIUS MEDICAL CARE AG & CO K : Buy rating from DZ Bank
MD
05/13FRESENIUS MEDICAL CARE AG & CO. KGAA : Ex-dividend day for final dividend
FA
05/12TRANSCRIPT : Fresenius Medical Care AG & Co. KGaA - Shareholder/Analyst Call
CI
05/12Fresenius Medical Care Celebrates Diversity and Unity of a Global Nurse Workforce
BU
05/12FRESENIUS MEDICAL CARE AG & CO. KGAA : Proxy Statments
CO
05/11FMC FRESENIUS MEDICAL CARE AG & CO K : Gets a Buy rating from UBS
MD
05/10FMC FRESENIUS MEDICAL CARE AG & CO K : Warburg Research gives a Neutral rating
MD
05/06FMC FRESENIUS MEDICAL CARE AG & CO K : Berenberg gives a Buy rating
MD
More news
Analyst Recommendations on FRESENIUS MEDICAL CARE AG & CO. KGAA
More recommendations
Financials (USD)
Sales 2022 20 056 M - -
Net income 2022 1 027 M - -
Net Debt 2022 11 768 M - -
P/E ratio 2022 17,3x
Yield 2022 2,22%
Capitalization 17 741 M 17 741 M -
EV / Sales 2022 1,47x
EV / Sales 2023 1,37x
Nbr of Employees 122 635
Free-Float 67,8%
Chart FRESENIUS MEDICAL CARE AG & CO. KGAA
Duration : Period :
Fresenius Medical Care AG & Co. KGaA Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends FRESENIUS MEDICAL CARE AG & CO. KGAA
Short TermMid-TermLong Term
TrendsBearishNeutralNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus HOLD
Number of Analysts 17
Last Close Price 60,54 $
Average target price 68,15 $
Spread / Average Target 12,6%
EPS Revisions
Managers and Directors
Rice Powell Chief Executive Officer
Helen Giza Chief Financial & Transformation Officer
Dieter Schenk Chairman-Supervisory Board
Franklin W. Maddux Executive VP-Clinical & Scientific Affairs
Rolf Allan Classon Vice Chairman-Supervisory Board